Objective: The present study was designed to investigate the effects of supplementation with carnitine and ubiquinone (Q10) to control CVD risk factors in HD patients under treatment with statin drugs. Type of study: Randomized double blind placebo controlled clinical trial. Population study: HD patients Sample size: 52 HD patients (25 women and 27 men; mean age 53.3+14.2 years). Inclusion criteria: 1) Patients under hemodialysis for at least one year; 2) Serum levels of lipoprotein (a) [Lp(a)] >20 mg/dl and homocysteine (Hcy) ≥15 mg/dl; 3) Willingness to participate and filling up the consent form. Exclusion criteria: 1) Patients with acute or chronic infection; 2) Patients taking carnitine, ubiquinone, vitamins A, E and C during the last month prior to the trial. Intervention: Patients were randomly divided into four groups, each of them received one of the following drugs: A) Carnitine 1000mg intravenously 3 times/week; B) Q10, 100 mg orally everyday; C) Carnitine+Q10; D) Placebo (n=13). Duration: 3 months Measurements: Fasting blood samples were collected at the beginning and at the end of trial for measuring serum levels of Lp(a), Hcy and malondialdehyde (MDA). Primary outcomes: Carnitine and/or Q10 supplementation may reduce serum levels of Lp(a), Hcy and MDA in HD patients under treatment with statin drugs.